Kornimate/medical-research-clean huggingface dataset:
a pilot study of evidence-based guided self-help for the treatment of binge eating

Conditions: Binge-Eating Disorder; Binge Eating

Summary: the purpose of the present pilot study is to evaluate the feasibility, acceptability and likely effectiveness of an evidence-based guided self-help intervention for binge eating and related disordered over-eating in those unable to access clinician provided treatments. if feasible, acceptable and likely to be effective, such interventions could be made available more widely as an early intervention to those in need. such interventions have the potential to improve quality of life by removing or ameliorating symptoms that impair psychological and social functioning. eligible participants will receive the guided self-help intervention - an evidence-based self help program in the form of a self-help book plus telephone support and encouragement to follow the program provided by specially trained help-line volunteers. support completing the self-help program will be provided over a period of 4 months and participants will be followed up for a year after completion of the intervention. participants will be asked to complete brief online assessments before starting the program, at the end of 4 months when they complete the program and at 6 month and 12 month follow up.


Eligibility criteria:
inclusion criteria: * participant contacted national eating disorder association (neda) with binge eating problems or disordered overeating * completed neda screen and study screen * age 18 and over * able to speak, understand and read english * consenting to guided self-help and completing study assessments exclusion criteria: * currently receiving treatment for an eating disorder * self-reported weight body mass index (bmi) \<20 * reported self-induced vomiting, laxative or diuretic use (purging) * reports suicidal ideation * breast feeding or pregnant * receiving treatment for co-existing psychiatric condition (e.g., bipolar disorder, psychotic illness, drug or alcohol dependence
anti-inflammatory effects of caffeine in chronic obstructive pulmonary disease (copd) subjects

Conditions: Chronic Obstructive Pulmonary Disease

Summary: nowadays it has become evident that a chronic systemic inflammation is present in patients suffering from chronic obstructive pulmonary disease (copd). the role of the nuclear enzyme poly(adenosine diphosphate-ribose)polymerase (parp) as a key mediator within these systemic inflammatory processes as well as in copd associated exercise intolerance and muscle weakness could recently been identified. the attenuating effect of dietary ingredients with parp inhibiting activity on systemic inflammation was supported by data from in vitro and in vivo studies, from other groups as well as from our own lab. we identified several caffeine metabolites as potent inhibitors of the most abundant parp-isoform parp-1 in-vitro, in animal models as well as in ex-vivo experiments with whole blood from copd patients. however, clinical data with respect to their anti-inflammatory effects in copd patients are currently not available for none of these substances. therefore, the current clinical pilot study is intended to establish for the first time clinical data (proof of principle) on the anti-inflammatory potential of caffeine metabolites.


Eligibility criteria:
inclusion criteria: * copd gold stage ii (50% ≤ fev1\< 80%) * crp plasma levels ≥ 3 mg/l * bmi \> 20 kg/m2 and \< 30 kg/m2 * diastolic blood pressure (dbp)=60-90 mmhg, systolic blood pressure (sbp)=100 150 mmhg exclusion criteria: * physical and/or mental disease or major surgery in the present or the past that might limit participation in or completion of the study * reported current or previous metabolic (e.g. diabetes), cardiovascular and/or renal diseases * known presence of a carcinoma * acute and/or chronic inflammatory condition such as arthritis, arthrosis, chronic colitis, etc. during three months before entry of the study * respiratory tract infection or exacerbation of copd for at least 8 weeks prior to the start of the study * change in treatment regime of the copd subjects for at least 8 weeks prior to the start of the study * use of laxatives, anti-diarrhoeal drugs and any other medication that can influence the uptake of the investigational products and/or influence their metabolism during the trial * during the month prior to the start of the study and during the study the use of antibiotics and/or local and systemic steroidal (glucocorticoids) and non-steroidal anti-inflammatory drugs (nsaid) * abnormal constant dietary eating habits and a coffee consumption of less than 3 cups per day (i.e. a usual daily intake of \<400 mg caffeine).

Keywords: copd caffeine chronic systemic inflammation oxidative stress supplementation stable copd gold stage ii with crp levels ≥ 3 mg/l
alteplase for treatment of empyema and complicated parapneumonic effusion

Conditions: Empyema; Pleural Effusion

Summary: the purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (cpe) using a daily versus twice daily alteplase regimen of two different dose strategies compared with saline placebo.

this is a randomized, double-blind, placebo-controlled pilot study. patients with empyema and complicated parapneumonic effusion who are felt to require fibrinolytic therapy will be considered for study enrollment. enrolled patients will be randomized to one of five potential treatment arms (saline placebo, 4 mg once daily, 4 mg twice daily, 10 mg once daily, or 10 mg twice daily) in a double-blinded manner.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent * age greater or equal to 18 yrs * presence of empyema or cpe exclusion criteria: * active internal bleeding * pregnancy * prior enrollment in this study * platelet count less than 100,000/mm3 * use of warfarin sodium if inr is greater than 1.7 * use of heparin unless the ptt is less than 1.5 times baseline normal * known neurological disorders * current or pre-existing bleeding dyscrasia * known allergy to alteplase

Keywords: alteplase empyema complicated parapneumonic effusion
botox or botox with esophageal dilation in patients with achalasia

Conditions: Achalasia

Summary: achalasia is a rare esophageal motility disorder. treatment of achalasia is aimed toward palliation of symptoms. these include botox injections to the lower esophageal sphincter (les), pneumatic dilation, surgical myotomy, and per-oral endoscopic myotomy (poem). botox injections are frequently used for patients that have significant comorbidities. the primary aim of this study is to assess symptomatic response of patient with achalasia to esophageal dilation and botox injection to the les compared to standard therapy of only botox injection.


Eligibility criteria:
inclusion criteria: * adults with known diagnosis of achalasia who are not candidates for definitive therapy with pneumatic dilation, surgical myotomy, or poem * patient undergoing routine care upper endoscopy for achalasia exclusion criteria: * less than 18 years old * previous surgery for reflux or peptic ulcer disease * significant medical conditions possibly placing subjects at risk to undergo endoscopy
safety and efficacy of cariprazine in patients with schizophrenia

Conditions: Schizophrenia

Summary: the objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.


Eligibility criteria:
inclusion criteria: * patients who have provided informed consent prior to any study specific procedures * patients currently meeting the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the structured clinical interview for diagnostic and statistical manual of mental disorders, fourth edition (scid) * patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ecg) * current psychotic episode (schizophrenia exacerbation) \< 2 weeks duration at visit 1 * structured clinical interview for the positive and negative syndrome scale (scipanss) total score ≥ 80 and ≤ 120 * cgi-s score ≥ 4 exclusion criteria: * schizoaffective disorder, schizophreniform disorder, and other psychotic disorders * bipolar i and ii disorder * pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders * dsm-iv-tr axis ii disorder of sufficient severity to interfere with participation in this study * women who are pregnant or breast feeding

Keywords: schizophrenia acute schizophrenia psychotropic drugs aripiprazole antipsychotic agents mental disorders dopamine agents central nervous system agents
ofdi capsule imaging in patients with atrial fibrillation undergone radio frequency (rf) ablation

Conditions: Atrial Fibrillation

Summary: 12 patients with atrial fibrillation, a kind of irregular heart beat who have undergone radio frequency (rf) ablation will be asked to swallow the capsule. as they swallow the capsule, images of the esophagus will be taken to see if the rf ablation caused any form of damage to the esophagus considering it being so close to the heart. after the capsule has been removed from the mouth, they will be asked about the tolerability of the capsule.

a total of 12 patients with a known diagnosis of atrial fibrillation who have previously undergone atrial rf ablation will be enrolled in the study. patients will be asked to swallow the ofdi capsule while being unsedated. the capsule is attached to a tether that allows the capsule operator to navigate the capsule as it progresses down the esophagus using natural propulsion called peristalsis as well as to bring it back up to pulled out of the mouth when the procedure is done. as the capsule progresses down the esophagus, multiple, two dimensional, microscopic cross- sectional images of the esophagus are acquired.

Eligibility criteria:
inclusion criteria: * subjects must be over 18 years of age * subjects must be able to give informed consent. * subjects must be referred to massachusetts general hospital (mgh) endoscopy for rf ablation treatment of their atrial fibrillation. exclusion criteria: * subjects with current esophageal strictures and dysphagia * or subjects with a prior history of intestinal strictures, prior gi surgery or intestinal crohn's disease. * or subjects with a known history of chronic aspiration. * or women who are currently pregnant.

Keywords: ofdi rf ablation atrial fibrillation imaging esophagus
effect of warmed irrigation in hip arthroscopy undergoing hip arthroscopy

Conditions: Femoro Acetabular Impingement; Pain, Postoperative

Summary: the purpose of this study is to determine if pre-warming of arthroscopic fluid reduces immediate post-surgical pain in hip arthroscopy patients. the investigators hypothesize there will be a significant decrease in the visual analog score (vas) measured 30 minutes post-operatively in the warmed fluid group compared to the control group. secondary outcome measures to be collected will include vas scores 60 minutes after surgery and on post-operative day (pod) one. additionally, the investigators will collect post-operative temperature measured 30 and 60 minutes post-operatively as well as morphine equivalent dosing in pacu and at the two-week follow up visit.

in the last two decades, hip arthroscopy for the treatment of femoral acetabular impingement has increased rapidly. currently, over 30k hip scopes are performed annually in the united states (incidence 1.06 per 10k). due to anatomical differences, hip arthroscopy procedures have the potential for significant fluid extravasation when compared to knee arthroscopy. a 2011 study on hip arthroscopy showed on average 9.68 liters of fluid were used for a standard hip procedure; of that 1.13 liters absorbed into the surrounding soft tissues. a recent systematic review and meta-analysis showed warming of arthroscopic fluids significantly decreased the risk of hypothermia during hip arthroscopy. additionally, active warming has been shown to decrease the rate of surgical site infection during numerous procedures. in total knee arthroplasty patients, a forced air warming gown significantly reduced narcotic pain consumption compared to standard care. however, the benefits of active warming for decreasing post-operative pain has not been studied in hip arthroscopy patients. specifically, the investigators were interested in the roll the pre-warming arthroscopic fluid plays in post-operative pain after hip arthroscopy. the purpose of this study is to see if pre-warming of arthroscopic fluid reduces immediate post-surgical pain and narcotic consumption in hip arthroscopy patients.

Eligibility criteria:
inclusion criteria: * all patients aged 18-65 years with a confirmed diagnosis of femoroacetabular impingement (fai) * required hip arthroscopy will be considered for the study * pre-operative history and physical exam * magnetic resonance imaging (mri) before being indicated for arthroscopic surgery exclusion criteria: * taking narcotic medications at baseline * have a history of complex regional pain syndrome, * have hip arthritis, * have undergone previous hip arthroscopic surgery, or * are deemed incapable by the principal investigator of completing the study.

Keywords: hip arthroscopy warmed fluids
evaluation of urine samples and their relation to urinary tract infection

Conditions: Urinary Tract Infections

Summary: the aim is to explore the human urine composition and its relation to urine tract infections


Eligibility criteria:
inclusion criteria: 1. have given written informed consent 2. be at least 18 years of age and have full legal capacity 3. for the 2 patient populations: use intermittent catheter on a daily basis due to neurogenic bladder or enlarged prostate and have used ic for at least 2 months 4. for healthy volunteers without utis: no diag-nosed utis within the last year 5. for healthy volunteers with recurrent utis: 3 or more utis within the last year or 2 utis within the last 6 months (treated with antibiotics) exclusion criteria: 1. be treated for urinary tract infection at time of enrolment 2. may not take prophylactic treatment for urinary tract infections (antibiotics only)
study on the efficacy of slow release insulin in cystic fibrosis patients with glucide intolerance and clinical decay

Conditions: Cystic Fibrosis; Glucose Intolerance

Summary: the purpose of this study is to evaluate whether the anticipated use of glargine in cf patients with glucose intolerance may prevent the worsening of nutritional status and pulmonary function.

diabetes mellitus may often complicate the cystic fibrosis course, and it is usually preceded by a condition defined as glucose intolerance, during which a significant decay of patient's general conditions is observed. a slow release insulin (glargine) has become available in the market for diabetic patients: its characteristics allow for a single daily dose, and no need of repeated daily monitoring of glycemia. in this randomized controlled clinical trial we evaluate whether the anticipated use of glargine in cf patients with glucose intolerance may prevent the worsening of nutritional status and pulmonary function. eligible patients who will accept to participate to this study will be randomly allocated in the group who will or will not receive glargine as additional supportive therapy. patients will in any case continue the cf therapy prescribed by their treating physicians and their usual diet. all the patients will be evaluated every three months to assess their nutritional, pulmonary and glycometabolic status. the follow-up will continue until the 18th month after the study entry.

Eligibility criteria:
inclusion criteria: * ascertained diagnosis of cf * age ≥ 10 years * glucide intolerance: 2 pathologic ogtt ( at 120' glucose value: \>140 mg% and \<200 mg%) at 2-6 months' interval between each other * at least one of the following conditions: * bmi (body mass index) \< 10th centile for age and sex (according to rolland cachera 1991) * loss of one bmi centile class for age and sex in the last year (according to rolland cachera 1991) * fev1 ≤ 80% of predicted * fev1 decrease ≥ 10% in the last year exclusion criteria: * specific contraindications for the use of glargine

Keywords: cystic fibrosis glucose intolerance
a multicentre, randomized as a double blind study, triple placebo, comparative of the efficacy and safety of an association secnidazol-ciprofloxacin compared with amoxicillin-clavulanic acid for the treatment of uncomplicated episode of diverticular sigmoïditis among adults

Conditions: Diverticular Sigmoïditis

Summary: the primary outcome measure is to compare efficacy of an association of secnidazol(2g)-ciprofloxacin(1g) (during 3 days) versus 3g of amoxicillin-clavulanic acid during 10 days for the treatment of uncomplicated episode of diverticular sigmoïditis among adults in clinical and biological cure. the cure rate will be evaluated at the second visit (14 days after the inclusion visit)


Eligibility criteria:
inclusion criteria: * adult * recovering of written and dated informed consent form * social security medical cover * left iliac fossa (lif) pain * moderate fever (\>37.8°c) * sensitivity/defence during lif palpation biological results : * crp \> 10mg/l * nfs \> 10g/l * neutrophil granulocytosis \> 75% * radiological results - presence to the scan :diverticul \& pericolic infiltration exclusion criteria: * patients treated by antibiotherapy in the last 15 days prior inclusion * patients treated by morphinic drug * patients treated by anticoagulant drug * pregnant or breast-feeding women * patients presenting allergy to active principal, to galactose * patients having taking part in another study in the last 3 months prior inclusion * patients unable to comply with the study requirements * patients presenting chronic affection inconsistent with the study * patients presenting high fever * patients presenting abdominal contracture * patients presenting immunosuppression * radiological sign of complication (abscess\>3cm) * patients presenting pathology inconsistent with efficacy evaluatio
dexmedetomidine versus triamcinolone treatment in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modalities are available for treatment of mild to moderate cts.

carpal tunnel syndrome (cts) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modaleties are available for treatment of mild to moderate cts. in case of failed conservative oral therapey, local hydro-dessction of the median nerve can be done with saline alone. local anethetics, steroids, hyalase,and ozone have been utilized to augment the symptoms reliefe. dexmeditomidine (dex) has been studied as adjuvant for nerve block to aumnet the pain reliefe. recently, it has been discovered that dex can offer some antinflammatory effects when injected in the perineural area. upon such discovery, the goal of this study has been built.

Eligibility criteria:
inclusion criteria: * adult patients * complaining of carpal tunnel syndrome of 3 month duration or more * diagnosed axonal neuropathy using electrodiagnosis , nerve conduction study exclusion criteria: * patient refusal * infection at the site of intervention * allergy to utilized drugs * diabetic * previous surgery in the site of injection * previous injection in the targeted site within the last year
study examining the safety and toxicity of stereotactic body radiotherapy (sbrt) followed by pcx12 immunotherapy delivered by intratumoral injection for the treatment of patients with locally advanced pancreatic adenocarcinoma (lapc)

Conditions: Pancreatic Adenocarcinoma

Summary: the purpose of this study is to determine whether a new treatment combining radiation therapy with pcx12 is safe and tolerable.

single center, open label, escalating dosage of pcx12 with standard of care practice for subjects who are diagnosed with adenocarcinoma of the head of the pancreas. subjects with undergo standard of care radiation therapy and then start on pcx12 therapy starting at 200 ng/kg of pcx12 escalating to a potential maximum dosage of 800 ng/kg of pcx12 with adjacent tolerability and safety guidelines.

Eligibility criteria:
inclusion criteria: * patient with pathologically proven diagnosis of adenocarcinoma of the pancreas * initially staged as locally advanced by national comprehensive cancer network (nccn) criteria of solid tumor contact with aorta, superior mesenteric artery (sma) or celiac axis \>180 degrees and/or unreconstructable superior mesenteric vein/portal vein (smv/pv) due to portal involvement or occlusion, tumor contact with most proximal draining jejunal branch into smv * have completed first line chemotherapy without progression or non-regional metastases * tumor is radiographically evident on ct scan after chemotherapy * tumor is anatomically amenable to sbrt, e.g. does not directly invade the stomach or bowel * tumor is amenable to intra-tumor injection under endoscopic ultrasound guidance * ecog performance status 0-2 * patients with childbearing potential must demonstrate a negative urine or serum pregnancy test * male or female subjects, aged at least 18 years; female subjects of childbearing potential may participate if adequate contraception is used during, and for at least the three months after study completion; male subjects with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during, and for at least the three months after study completion; adequate contraception is defined as resulting in a failure rate of less than 1% per year * patient must be able to understand and willingly sign study specific informed consent prior to study entry * anticipated life expectancy ≥ 12 weeks * patients aged at least 18 years of age exclusion criteria: * progression of disease or metastatic disease after first line systemic therapy * prior radiation treatment or surgical resection of any pancreatic malignancy * inability to tolerate sbrt, endoscopic ultrasound or il-12 injection procedure * lack of radiographically evident disease after first line chemotherapy * severe, active comorbidity that shortens the patient's life expectancy to less than 12 weeks * history of past malignancy * patient who is pregnant and/or breastfeeding * inability to comply with other required protocol procedures including required biopsies

Keywords: pancreatic adenocarcinoma pancreatic cancer pcx12 il-12